However, patients with unmethylated MGMT promoter in the tumor showed only a marginal benefit from addition of temozolomide, with a median survival of 12.7 months (95% CI 11.6–14.4) compared with 11.8 months (9.7–14.1) for patients treated with radiotherapy alone (HR 0.69, 95% CI 0.47–1.02) [44]. The gene discussed is MGMT; the disease is neoplasm.